842140-51-6

Basic information

• Product Name: 3,5-DIFLUOROBENZOYLACETONITRILE
• Synonyms: BUTTPARK 81\09-13;3,5-DIFLUOROBENZOYLACETONITRILE;3,5-Difluoro-b-oxo-benzenepropanenitrile;3-(3,5-Difluoro-phenyl)-3-oxo-propionitrile
• CAS NO: 842140-51-6
• Molecular Formula: C₉H₅F₂NO
• Molecular Weight: 181.14
• Mol File: 842140-51-6.mol

Chemical Properties

• Melting Point: 102-105°C
• Boiling Point: 303.7°C at 760 mmHg
• Flash Point: 137.5°C
• Appearance: /
• Density: 1.3g/cm³
• Vapor Pressure: 0.000917mmHg at 25°C
• Refractive Index: 1.497
• CAS DataBase Reference: 3,5-DIFLUOROBENZOYLACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DIFLUOROBENZOYLACETONITRILE(842140-51-6)
• EPA Substance Registry System: 3,5-DIFLUOROBENZOYLACETONITRILE(842140-51-6)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 842140-51-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3,5-Difluorobenzoylacetonitrile is used as a key intermediate in the synthesis of novel thienopyrimidones, which are TRPA1 inhibitors. TRPA1, or the transient receptor potential ankyrin 1, is a calcium-permeable nonselective cation channel expressed in sensory neurons and other cell types. Inhibition of TRPA1 has been implicated in the treatment of various conditions, including pain, inflammation, and respiratory diseases.
The use of 3,5-difluorobenzoylacetonitrile in the preparation of thienopyrimidones as TRPA1 inhibitors highlights its potential role in the development of new therapeutic agents with improved efficacy and safety profiles. By targeting TRPA1, these compounds may offer innovative treatment options for patients suffering from a range of disorders associated with the activation of this ion channel.

InChI:InChI=1/C9H5F2NO/c10-7-3-6(4-8(11)5-7)9(13)1-2-12/h3-5H,1H2

Upstream product

• 220607-75-0 2-bromo-1-(3,5-difluorophenyl)ethanone 
• 151-50-8 potassium cyanide 
• 2265-91-0 1,3-difluoro-5-iodobenzene 
• 350-19-6 ethyl 3,5-difluorobenzoate 
• 75-05-8 acetonitrile 
• 18293-53-3 2-trimethylsilylacetonitrile 
• 13939-06-5 molybdenum hexacarbonyl 

Downstream Products

• 1269628-70-7 2-(3,5-difluorophenyl)-7-methoxybenzo[b][1,8]naphthyridine-3-carbonitrile 
• 1269628-61-6 2-(3,5-difluorophenyl)benzo[b][1,8]naphthyridine-3-carbonitrile 

Relevant articles and documents

One-pot synthesis of benzoylacetonitriles through sequential Pd-catalyzed carbonylation and decarboxylation

Benzoylacetonitrile were prepared through sequential carbonylation and decarboxylation. The palladium-catalyzed carbonylation of aryl iodides and methyl cyanoacetate using Mo(CO)6 as a carbon monoxide source afforded beta-keto cyanoesters, and then the subsequent reaction with Li/H2O produced the desired benzoylacetonitriles.

TRI - AND TETRACYCLIC PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS ANTINEOPLASTIC AGENT

The present invention relates to compounds of following general formula (I): and to the pharmaceutically acceptable salts of same, the tautomers of same, the stereoisomers or mixture of stereoisomers in any proportions of same, such as a mixture of enantiomers, notably a racemic mixture, as well as to methods for preparing same and uses of same, notably as an antineoplastic agent.

PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME

Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein.

Palladium-catalyzed carbonylation with Mo(CO)for the synthesis of benzoylacetonitriles

Benzoylacetonitriles were synthesized by the palladium-catalyzed carbonylation of aryl iodides and trimethylsilylacetonitrile using Mo(CO)as a carbon monoxide source. Pd(PPhCland CuFwere employed as the catalyst and activator, respectively. A variety of aryl iodides bearing alkyl, alkoxy, fluoro, chloro, bromo, nitrile, ester, and ketone groups afforded the corresponding benzoylacetonitriles in moderate to good yields. Georg Thieme Verlag Stuttgart ? New York.

ARALKYL AMINES AS CANNABINOID RECEPTOR MODULATORS

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson’s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, including alcohol and nicotine addiction, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.